Gene-Targeted therapy fails to outperform standard care in advanced cancer trial
NCT ID NCT01771458
First seen Jan 10, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This study tested whether choosing cancer drugs based on the genetic profile of a patient's tumor works better than standard chemotherapy for people with advanced solid tumors that no longer respond to usual treatments. Over 700 participants had a biopsy to identify genetic changes, then were randomly assigned to receive either a targeted drug matched to their tumor's profile or standard treatment chosen by their doctor. The main goal was to see if the personalized approach could slow cancer growth longer than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECCURENT/METASTATIC SOLID TUMOR DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, 54500, France
-
Centre Leon Berard
Lyon, 69373, France
-
Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc
Dijon, 21079, France
-
Insitut Curie
Paris, 75248, France
-
Institut Claudius Régaud
Toulouse, 31052, France
-
Institut Curie Hopital Rene Huguenin
Saint-Cloud, 92210, France
-
Institut Paoli Calmettes
Marseille, 13009, France
-
Institut de cancérologie de l'Ouest Centre René Gauducheau
Saint-Herblain, 44000, France
Conditions
Explore the condition pages connected to this study.